Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile for acute gout flare
NL-OMON53551Phase 2Not yet recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gout comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
dapansutrile
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON53551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53551.